BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28567859)

  • 1. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
    Jahan N; Lee JM; Shah K; Wakimoto H
    Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.
    Tamura K; Wakimoto H; Agarwal AS; Rabkin SD; Bhere D; Martuza RL; Kuroda T; Kasmieh R; Shah K
    Mol Ther; 2013 Jan; 21(1):68-77. PubMed ID: 22929661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
    Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
    Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
    Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
    Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
    Kanai R; Wakimoto H; Martuza RL; Rabkin SD
    Clin Cancer Res; 2011 Jun; 17(11):3686-96. PubMed ID: 21505062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
    Sgubin D; Wakimoto H; Kanai R; Rabkin SD; Martuza RL
    Stem Cells Transl Med; 2012 Apr; 1(4):322-32. PubMed ID: 23197811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
    Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
    Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
    J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
    Saha D; Rabkin SD; Martuza RL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K; Sanchez Gil J; Rabkin SD
    Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors.
    Martinez-Quintanilla J; Bhere D; Heidari P; He D; Mahmood U; Shah K
    Stem Cells; 2013 Aug; 31(8):1706-14. PubMed ID: 23389839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
    Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
    Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
    mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.